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Abstract
Clathrin-mediated endocytosis includes cycles of assembly and disassembly of the clathrin-coated vesicle constituents.
How these cycles are regulated is still not fully known but previous studies have indicated that phosphorylation of coat
subunits may play a role. Here we describe that L2-adaptin undergoes cycles of phosphorylation/de-phosphorylation in intact
cells. Thus, L2-adaptin was constitutively de-phosphorylated by serine/threonine protein phosphatase 2A and
phosphorylated by a staurosporine-sensitive kinase in vivo. Confocal laser scanning microscopy demonstrated that
phosphorylated AP2 complexes were found more evenly distributed at the plasma membrane compared to non-
phosphorylated AP2 complexes which were found in aggregates. Finally, we found that phosphorylation of L2-adaptin
correlated with inhibition of clathrin-mediated endocytosis. Our results support the hypothesis that phosphorylation/
de-phosphorylation of coat proteins plays a regulatory role in the assembly/disassembly cycle of clathrin-coated
vesicles. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Clathrin-mediated endocytosis is essential in endo-
cytosis of plasma membrane receptors and their li-
gands. The major coat constituents of clathrin-
coated vesicles are clathrin and adaptor protein
(AP) complexes [1^3]. Clathrin consists of three
heavy chains each bound to one of two light chains,
a or b. To date, four AP complexes known as AP1,
AP2, AP3, and the newly discovered AP4 have been
described [4^6]. Whereas AP1, AP3, and possibly
AP4 are involved in intracellular transport events,
AP2 is involved in clathrin-mediated endocytosis
from the plasma membrane. All four AP complexes
consist of two large subunits (Q, K, N, or O and L1, L2,
L3, or L4, V90^140 kDa) called adaptins, one me-
dium subunit (W1, W2, W3, or W4, V50 kDa) and one
small subunit (c1, c2, c3, or c4, V20 kDa). The L1-
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and L2-adaptins interact with clathrin through a
clathrin box sequence and induce clathrin to form
cages [7^9]. The W2-chain binds tyrosine-based recep-
tor-sorting motifs in the form YppÖ where Y is ty-
rosine, p is a polar residue, and Ö is a residue with a
bulky hydrophobic side chain [10]. Leucine-based re-
ceptor-sorting motifs are recognized by either the L2-
or the W2-chains [11^13]. The K-adaptin has been
reported to interact with accessory factors involved
in clathrin coat assembly such as dynamin, amphi-
physin, epsin and Eps15 [14^18]. The exact functions
of the Q-, N-, O-adaptins and the c-subunits still have
to be determined.
Clathrin-mediated endocytosis includes cycles of
assembly and disassembly of the clathrin-coated
vesicle constituents. Formation of a clathrin-coated
vesicle is initiated by recruitment of AP2 complexes
from the cytosol to the plasma membrane. Addition-
al coat constituents are recruited and assembled step-
wise, incrementally deforming the attached segment
of the membrane in process. The vesicle is released
encased in the clathrin coat, which is then discarded
to allow the vesicle to fuse with the target compart-
ment [3,19]. The uncoating ATPase, hsc70, probably
mediates the release of clathrin from the vesicle,
however, hsc70 does not release AP2 [20^22]. Factors
required for release of AP2 from coated vesicles re-
main to be identi¢ed.
Interestingly, clathrin [23,24], the AP2 complex
proteins (K, L2, W2, c2) [25], dynamin 1, and amphi-
physin [26^28] all have the ability to be phosphory-
lated on either serine or threonine. Thus, phosphor-
ylation/de-phosphorylation of coat proteins might
play a regulatory role in the assembly/disassembly
cycles of clathrin-coated vesicles. Accordingly, results
from previous studies have suggested that phosphor-
ylation of coat proteins may play a role in control-
ling the assembly state [25,29^31]. Thus, it was found
that phosphorylated AP2 complexes are unable to
bind to clathrin cages in vitro and that phosphory-
lated AP2 complexes mainly are localized to the cy-
tosol [25]. Likewise, interaction of amphiphysin 1
with the major coat constituents in vitro is inhibited
by phosphorylation of amphiphysin 1 [31]. If phos-
phorylation/de-phosphorylation of coat proteins
plays an important role in assembly/disassembly of
clathrin-coated vesicles it should be expected that a
constitutive phosphorylation and de-phosphorylation
of coat proteins takes place in intact cells. However,
the kinases and phosphatases responsible for phos-
phorylation/de-phosphorylation of coat proteins in
vivo remain to be identi¢ed.
The aim of this study was to determine whether
L-adaptin undergoes cycles of phosphorylation/de-
phosphorylation in intact cells and if so, to further
characterize potential kinases and phosphatases in-
volved in this process. We found that L-adaptin
was constitutively de-phosphorylated by serine/threo-
nine protein phosphatase (PP) 2A and phosphorylat-
ed by a staurosporine-sensitive kinase in vivo. Con-
focal laser scanning microscopy demonstrated that
phosphorylated AP2 complexes were found at the
plasma membrane. However, compared to non-phos-
phorylated AP2 that were found in aggregates, phos-
phorylated AP2 complexes were more evenly distrib-
uted. Finally, we found that phosphorylation of
L2-adaptin correlated with inhibition of clathrin-
mediated endocytosis of receptors containing either
leucine- or tyrosine-based receptor-sorting motifs.
2. Materials and methods
2.1. Cells, antibodies, and chemicals
The human Jurkat T cell line J76 and the trans-
fectant CD4/3-SA, JGN transfected with a chimeric
CD4/CD3Q molecule as previously described [32,33],
were cultured in RPMI 1640 medium supplemented
with penicillin 2U105 U/l (Leo Pharmaceutical Prod-
ucts, Ballerup, Denmark), streptomycin 50 mg/l
(Merck, Darmstadt, Germany), and 10% (vol/vol)
fetal calf serum (FCS) (Life Technologies, Paisley,
UK) at 37‡C in 5% CO2. The anti-L-adaptin mono-
clonal antibody (mAb) 100/1 recognizing L1- and
L2-adaptin was obtained from Sigma Chemicals
(St. Louis, CA, USA). Anti-K-adaptin was from On-
cogene Research Products (Cambridge, MA, USA).
Phycoerythrin (PE)-conjugated mouse anti-human
CD3O mAb (UCHT1) and peroxidase-conjugated
rabbit anti-mouse Ig were obtained from Dakopatts
(Glostrup, Denmark). The anti-TCR mAb F101.01
was produced in our own laboratory [34]. PE-conju-
gated anti-mouse CD4 was from Pharmingen (San
Diego, CA, USA). PE-conjugated F(ab)2 fragments
of goat anti-mouse Ig H+L was obtained from Jack-
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son Immunoresearch (West Grove, PA, USA). The
serine/threonine protein phosphatase inhibitors tau-
tomycin and okadaic acid were from Calbiochem (La
Jolla, CA, USA) and calyculin A was from Biomol
(Plymouth Meeting, PA, USA). Calf intestinal alka-
line phosphatase (CIAP) was from New England
Biolabs (Beverly, MA, USA). Puri¢ed PP1 from rab-
bit skeletal muscle and puri¢ed PP2A from human
red blood cells were obtained from Upstate Biotech-
nology (Lake Placid, NY, USA). The phorbol ester
phorbol-12,13-dibutyrate (PDB) was from Sigma
Chemicals. Transferrin^£uorescein was from Boehr-
inger-Mannheim (Mannheim, Germany) and defer-
oxamine was obtained from Ciba-Geigy AG (Basel,
Switzerland). Fluorescein^dextran, 70 000 MW, was
from Molecular Probes (Leiden, The Netherlands).
The kinase inhibitors staurosporine, KT5720,
KT5823, bisindolylmaleimide I, KN93, and 5,6-
dichloro-1-L-D-ribofuranosylbenzimidazole (DRB)
were all from Calbiochem. The protein kinase A
(PKA) activators 8-CPT-cAMP or sp-cAMPS or
the PKA inhibitor rp-cAMPS were from Biomol.
2.2. Immunoprecipitation and Western blot
For immunoprecipitation cells (1U107) were ad-
justed to 1U106 cells per ml of medium (RPMI
1640+10% FCS) and incubated for 1 h at 37‡C
with or without inhibitor. Subsequently the cells
were washed three times in ice-cold PBS and lysed
in 0.5 ml lysis bu¡er (20 mM Tris^HCl, pH 8.0, 137
mM NaCl, 10% glycerol, 1% NP-40, 10 mM EDTA,
10 mM NaF, 1 mM aprotinin, 1 mM Na3VO4, 1 mM
phenylmethylsulfonyl £uoride, 100 nM calyculin) for
20 min on ice. The lysates were precleared three
times with protein A-Sepharose (PA) beads (Amer-
sham Pharmacia Biotech, Sweden), incubated with
20 Wl anti-K-adaptin mAb for 1.5 h and subsequently
incubated with PA for another 1.5 h. The PA beads
were washed three times in lysis bu¡er, before elution
of the proteins from the beads by boiling for 5 min in
sample bu¡er (50 mM Tris^HCl, pH 6.8, 2% SDS,
10% glycerol, 0.01% bromophenol, 2% mercaptoeth-
anol). Samples were electrophoresed in 10% poly-
acrylamide gels and subsequently analyzed by West-
ern blot as described below.
For Western blots, cells were adjusted to 1U106
cells per ml of medium (RPMI 1640+10% FCS) and
incubated at 37‡C for 1 h or the time indicated with
the various inhibitors. The cells were subsequently
lysed in lysis bu¡er (20 mM Tris^HCl, pH 8.0,
137 mM NaCl, 10% glycerol, 1% NP-40) for 20 min
on ice. The lysates were centrifuged for 10 min at
4500Ug, 4‡C and subsequently boiled for 5 min in
sample bu¡er. Following SDS^PAGE, the proteins
were transferred to nitrocellulose membranes (Hy-
bond, Amersham Pharmacia Biotech) by semi-dry
blotting. Membranes were blocked in 1% BSA, 4%
non-fat milk in PBS for 1 h and subsequently incu-
bated with anti-L-adaptin mAb (1:500 dilution) over-
night. Detection of anti-L-adaptin was performed us-
ing a 1:2000 dilution of horseradish peroxidase-
conjugated rabbit anti-mouse Ig. Bound horseradish
peroxidase-conjugated rabbit anti-mouse Ig was vi-
sualized using enhanced chemiluminescence (ECL,
Amersham Pharmacia Biotech).
2.3. Confocal laser scanning microscopy
Cells were washed in PBS and ¢xed for 10 min
with 2% paraformaldehyde/PBS. The cells were per-
meabilized for 10 min at room temperature with
washing bu¡er (HEPES-bu¡ered PBS, containing
0.1% saponin) and stained with anti-K-adaptin
mAb at room temperature for 20 min. Cells were
washed three times in washing bu¡er and stained
with Cy5-conjugated F(ab)2 fragments of donkey
anti-mouse IgG H+L (Jackson Immunoresearch,
West Grove, PA, USA) at room temperature for
20 min. Confocal microscopy was performed on a
Zeiss LSM510 connected to a Zeiss Axiovert 100 M
microscope (Carl Zeiss Ltd., Jena, Germany). Cy5
£uorescence was detected using long pass ¢lter LP
650.
2.4. TCR, transferrin receptor, and CD4/3-SA
endocytosis
For TCR endocytosis, cells were adjusted to
1U106 cells per ml of medium (RPMI 1640+10%
FCS) and pre-incubated at 37‡C for 1 h with the
indicated phosphatase inhibitors. PDB or the TCR
ligand mAb F101.01 was added and the cells were
incubated for one additional hour at 37‡C. Subse-
quently, the cells were transferred to ice-cold PBS
containing 2% FCS and 0.1% NaN3 and washed
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twice. Cells treated with PDB were stained directly
with PE-conjugated anti-CDO and analyzed using a
FACScalibur (Becton Dickinson, Mountain View,
CA, USA). Cells stimulated with F101.01 were
stained with F101.01 followed by PE-conjugated
F(ab)2 fragments of goat anti-mouse Ig H+L.
Mean £uorescence intensity (MFI) was recorded
and used in the calculation of percent antibody bind-
ing (MFI of cells treated with PDB/F101.01 and
phosphatase inhibitor)/(MFI of cells treated only
with phosphatase inhibitor)U100%.
For transferrin endocytosis, cells were adjusted to
1U106 cells per ml of medium (RPMI 1640+10%
FCS) and pre-incubated at 37‡C for 1 h with the
indicated phosphatase inhibitors. The cells were sub-
sequently incubated at 37‡C with £uorescein^trans-
ferrin (4 Wg/ml). At the indicated times aliquots of
the cell suspension were washed in ice-cold PBS con-
taining 2% FCS and 0.1% NaN3 and incubated for
20 min at 4‡C with 50 mM citric acid, pH 5.0,
100 mM NaCl, 100 WM deferoxamine and 0.2%
BSA to strip of cell surface bound transferrin. After
20 min the cells were washed once with ice-cold PBS
and incubated for 15 min at 4‡C with PBS containing
100 mM deferoxamine and 0.2% BSA. Subsequently,
the cells were analyzed on a FACScalibur. MFI was
recorded and used in the calculation of percent en-
docytosed transferrin^£uorescein (MFI of phospha-
tase inhibitor treated cells)/(MFI of untreated cells at
30 min)U100%.
For CD4/3-SA endocytosis, cells were incubated at
a cell density of 1U106 cells per ml medium at 37‡C
or 4‡C with PE-conjugated anti-CD4 mAb. At the
time indicated aliquots of cell suspension were
washed in ice-cold PBS containing 2% FCS and
0.1% NaN3 and immediately treated with 300 Wl
0.5 M NaCl, 0.5 M acetic acid, pH 2.2 for 10 s.
The acid resistant £uorescence of the cells (represent-
ing internalized anti-CD4 mAb) was measured in the
FACScalibur. The percentage of internalized anti-
CD4 mAb to cell surface bound anti-CD4 mAb
was subsequently calculated using the equation:
((HAR3CAR)/CT)U100%, where HAR is the MFI
of acid treated cells incubated at 37‡C, CAR is the
MFI of acid treated cells incubated at 4‡C, and CT is
the MFI of untreated cells incubated at 4‡C.
3. Results
3.1. L2-Adaptin is constitutively de-phosphorylated by
PP2A
It has been demonstrated that K- and L2-adaptin
of AP2 and L1-adaptin of AP1 are phosphorylated
on serines in vivo [25]. The phosphorylated adaptors
were mainly found in the cytosol and their binding to
clathrin cages was impaired in vitro. These observa-
tions indicated that adaptor subunits must be de-
phosphorylated to participate in clathrin-mediated
vesicular transport. To determine whether the phos-
phatases PP1 and/or PP2A were involved in L2-adap-
tin de-phosphorylation, Jurkat cells were treated with
the phosphatase inhibitor calyculin A, a potent in-
hibitor of PP1 and PP2A [35]. Cells were incubated
with 60 nM calyculin A for 1 h and subsequently
lysed. L2-Adaptin was co-precipitated from the lysate
using the K-adaptin mAb and the precipitates were
run on SDS^PAGE, transferred to membranes and
immunoblotted with anti-L-adaptin mAb 100/1. The
K-adaptin mAb clearly co-precipitated L2-adaptin
(Fig. 1A, lane 1 versus lane 2). Interestingly, treat-
ment with calyculin A induced a mobility shift of L2-
adaptin, which could be caused by L2-adaptin phos-
phorylation (Fig. 1A). Parallel analyses of whole-cell
lysates and K-adaptin immunoprecipitates gave iden-
tical results, which allowed us directly to analyze
whole-cell lysates in the following experiments. To
determine the dose-dependency of the calyculin A-
mediated mobility shift of L-adaptin, cells were incu-
bated with di¡erent concentrations of calyculin A for
1 h and subsequently lysed. The mobility shift of
L-adaptin was observed at 40 nM calyculin A and
was almost complete at 120 nM (Fig. 1B). To inves-
tigate whether the mobility shift actually was caused
by phosphorylation of L-adaptin, lysates from cells
treated with 120 nM calyculin A were treated with
alkaline phosphatase. As shown in Fig. 1B, alkaline
phosphatase treatment of the lysate completely re-
versed the mobility shift, demonstrating that the ca-
lyculin A induced mobility shift of L-adaptin was
caused by phosphorylation of L-adaptin. To deter-
mine the kinetics of L-adaptin phosphorylation, cells
were incubated with 60 nM calyculin A for di¡erent
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periods. Following calyculin A treatment, the cells
were lysed and analyzed as described above. L-Adap-
tin phosphorylation was observed within 10 min and
the mobility shift was almost complete after 40 min
(Fig. 1C).
Calyculin A does not signi¢cantly discriminate be-
tween PP1 and PP2A [35]. To determine the main
phosphatase involved in L-adaptin de-phosphoryla-
tion, cells were treated with okadaic acid, a potent
PP2A inhibitor, or tautomycin that preferably inhib-
its PP1 [35,36]. Okadaic acid induced the same kind
of mobility shift of L-adaptin as calyculin A, whereas
tautomycin did not indicating that PP2A and not
PP1 de-phosphorylated L-adaptin (Fig. 1B, lanes 7
and 8). This was further supported by the observa-
tion that treatment of phosphorylated L-adaptin in
vitro with puri¢ed PP2A completely de-phosphory-
lated L-adaptin from as well whole-cell lysate as well
puri¢ed L2-adaptin. In contrast, treatment with pu-
ri¢ed PP1 only partially de-phosphorylated L-adap-
tin (Fig. 2). Finally, addition of calyculin A (120 nM)
to the lysis bu¡er of untreated cells did not cause the
appearance of phosphorylated L-adaptin, demon-
strating that constitutively phosphorylation of
L-adaptin took place in intact cells and not in the
cell lysate (data not shown).
Taken together, these results demonstrated that
L2-adaptin is constitutively de-phosphorylated in
vivo by a phosphatase belonging to the PP2A family.
3.2. L-Adaptin is phosphorylated by a
staurosporine-sensitive kinase
The observation that L-adaptin was constitutively
de-phosphorylated implied that L-adaptin also had
to be constitutively phosphorylated. In an attempt
to identify the kinase(s) responsible for phosphoryla-
Fig. 2. L2-Adaptin is a substrate for PP2A. Cells were treated
with (lanes 2^7) or without (lane 1) calyculin A (Cal, 60 nM)
for 1 h. The cells were subsequently lysed. Whole-cell lysates
(lanes 1^5) and anti-K-adaptin precipitates (lanes 6 and 7) were
treated with puri¢ed PP2A (0.5 units, lanes 3 and 7), puri¢ed
PP1 (0.5 units, lane 4), left untreated at 37‡C (lanes 5 and 6),
or untreated on ice (lanes 1 and 2) for 2 h. The lysates were
thereafter analyzed as described above.
Fig. 1. L2-Adaptin is constitutively de-phosphorylated by PP2A.
(A) Cells were incubated without (lanes 1^3) or with (lanes 4^6)
60 nM of calyculin A for 1 h. The cells were subsequently lysed
and the lysates were either precipitated with anti-K-adaptin
mAb (lanes 1 and 4), with irrelevant mAb (lanes 2 and 5), or
left untreated (lanes 3 and 6). The precipitated material and
whole-cell lysates were subsequently run on SDS^PAGE, trans-
ferred to nitrocellulose membranes and immunoblotted with the
anti-L-adaptin mAb 100/1. (B) Cells were incubated with in-
creasing concentrations of calyculin A (Cal, lanes 1^6), okadaic
acid (OA, lane 7) or tautomycin (Tau, lane 8) for 1 h. The cells
were subsequently lysed and the lysates were either treated with
calf intestinal alkaline phosphatase (CIAP, lane 6) for 2 h at
37‡C or kept on ice (lanes 1^5, 7, and 8). The lysates were run
on SDS^PAGE, transferred to nitrocellulose membranes and
immunoblotted with the anti-L-adaptin mAb 100/1. (C) Cells
were incubated with calyculin A (60 nM) for the periods indi-
cated. The cells were subsequently lysed and the lysates ana-
lyzed as described above.
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tion of L-adaptin, cells were treated with di¡erent
kinase inhibitors prior to incubation with calyculin
A. The cells were lysed and the lysates run on SDS^
PAGE, transferred to membranes and immunoblot-
ted with anti-L-adaptin mAb. No or reduced levels of
L-adaptin phosphorylation should be observed fol-
lowing calyculin A treatment if the kinase inhibitor
tested inhibited the L-adaptin kinase. The broad-
spectrum kinase inhibitor staurosporine almost com-
pletely abolished L-adaptin phosphorylation (Fig.
3A). Furthermore, the protein kinase A (PKA) in-
hibitor KT5720 reduced phosphorylation of L-adap-
tin. None of the other kinase inhibitors a¡ected
L-adaptin phosphorylation. Whether PKA actually
was involved in L-adaptin phosphorylation was
next analyzed using speci¢c inhibitors or activators
of PKA. If PKA was involved an increase in L-adap-
tin phosphorylation would be expected in cells
treated with PKA activators and a reduction in
L-adaptin phosphorylation should be observed in
cells treated with PKA inhibitors. However, neither
the PKA activators 8-CPT-cAMP and sp-cAMPS
nor the PKA inhibitor rp-cAMPS a¡ected L-adaptin
phosphorylation (Fig. 3B) indicating that PKA was
not involved in L-adaptin phosphorylation. To fur-
ther characterize the staurosporine-sensitive L-adap-
tin kinase, cells were pre-incubated with various con-
centrations of staurosporine for 1 h followed by co-
incubation with calyculin A (60 nM). A reduction in
L-adaptin phosphorylation was observed in cells
treated with 25 nM staurosporine and L-adaptin
phosphorylation was almost totally abolished in cells
treated with 100 nM staurosporine (Fig. 3C). Taken
together, these results demonstrated that L-adaptin is
constitutively phosphorylated by a staurosporine-
sensitive kinase.
3.3. Phosphorylation in£uences the distribution of
AP2 complexes at the plasma membrane
In a previous study on bovine kidney cells, phos-
phorylated AP2 complexes predominated in the cy-
Fig. 3. L-Adaptin is phosphorylated by a staurosporine-sensitive
kinase. (A) Cells were pre-incubated for 1 h with the broad ki-
nase inhibitor staurosporine (1000 nM, lane 3), the PKA inhibi-
tor KT5720 (1000 nM, lane 4), the PKC inhibitor bisindolylma-
leimide I (1000 nM, lane 5), the protein kinase G inhibitor
KT5823 (1000 nM, lane 6), the calmodulin kinase II inhibitor
KN93 (10 WM, lane 7) and the casein kinase II inhibitor DRB
(100 WM, lane 8) before co-incubation with (lanes 2^8) or with-
out (lane 1) calyculin A (60 nM) for an additional 1 h. The
cells were subsequently lysed and the lysates run on SDS^
PAGE, transferred to nitrocellulose membranes and immuno-
blotted with the anti-L-adaptin mAb 100/1. (B) Cells were pre-
incubated for 1 h with the PKA activators 8-CPT-cAMP
(500 WM, lane 3) or sp-cAMPS (100 WM, lane 4) or the PKA
inhibitor rp-cAMPS (200 WM, lane 5) before co-incubation with
(lanes 2 and 5) or without (lanes 1, 3, and 4) calyculin A
(60 nM) for an additional 1 h. The cells were subsequently
lysed and the lysates analyzed as described above. (C) Cells
were pre-incubated for 1 h with increasing concentrations of
staurosporine before co-incubation with (lanes 2^9) or without
(lane 1) calyculin A (60 nM) for an additional 1 h. The cells
were subsequently lysed and the lysates analyzed as described
above.
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tosol in comparison to AP2 complexes associated
with the plasma membrane [25]. To determine the
intracellular distribution of AP2 complexes contain-
ing phosphorylated L2-adaptin in human T cells,
cells were treated with 120 nM calyculin A previously
shown to induce phosphorylation of the vast major-
ity of L-adaptin molecules (Fig. 1B, lane 5). The cells
were subsequently ¢xed, permeabilized, stained with
anti-K-adaptin mAb and analyzed by confocal laser
scanning microscopy. The staining pattern of calycu-
lin A treated cells di¡ered from untreated cells (Fig.
4). Thus, whereas AP2 complexes in untreated cells
were mainly found in aggregates at the plasma mem-
brane, AP2 complexes in calyculin A treated cells
were more evenly distributed at the plasma mem-
brane. However, there did not seem to be a signi¢-
cant redistribution of AP2 complexes from the plas-
ma membrane to the cytosol as a result of the
induced phosphorylation.
3.4. Phosphorylation-induced T cell receptor
endocytosis is blocked by PP2A inhibitors
Previous studies have described an impaired inter-
action between proteins involved in clathrin-medi-
ated endocytosis following their phosphorylation
[25,31]. These observations suggest that clathrin-
mediated endocytosis probably is inhibited during
circumstances that promote phosphorylation. First,
we used the T cell receptor (TCR) as a model to
study the e¡ect of phosphatase inhibitors on clath-
rin-mediated endocytosis. TCR endocytosis can be
induced by two di¡erent pathways dependent on ei-
ther tyrosine or serine phosphorylation of the TCR
components [37]. Thus, the TCR becomes tyrosine
phosphorylated and subsequently endocytosed fol-
lowing ligand binding. Likewise, the TCR is endocy-
tosed following protein kinase C (PKC)-mediated
phosphorylation of serine 126 in the di-leucine-based
(Ser-Asp-Lys-Gln-Thr-Leu-Leu) receptor-sorting mo-
tif of CD3Q [38]. In both pathways, TCR endocytosis
takes place via clathrin-coated pits and vesicles
[32,38^40]. To determine the e¡ect of the phospha-
tase inhibitors on TCR endocytosis, cells were pre-
incubated with increasing concentrations of either
calyculin A, okadaic acid or tautomycin followed
by incubation with a ¢xed concentration of either
the TCR ligand mAb F101.01 or the PKC activator
PDB. Calyculin A and okadaic acid inhibited both
ligand- and PKC-mediated TCR endocytosis, where-
as tautomycin showed only a minor e¡ect at the
highest concentrations tested (Fig. 5A^C). Interest-
ingly, the concentrations of calyculin A and okadaic
acid required to inhibit TCR endocytosis were coin-
cident with the concentrations required to inhibit de-
phosphorylation of L-adaptin. To analyze whether
higher concentrations of PDB could overrule the in-
hibitory e¡ect of calyculin A and okadaic acid on
TCR endocytosis the following experiments were
performed. Cells were pre-incubated with a ¢xed
concentration of calyculin A (60 nM) or okadaic
acid (500 nM) shown to inhibit TCR endocytosis
or tautomycin (1000 nM) followed by incubation
with increasing concentrations of PDB. Even the
highest concentrations of PDB did not rescue PKC-
mediated TCR endocytosis in the presence of calycu-
lin A or okadaic acid (Fig. 5D). Again, tautomycin
showed no inhibitory e¡ect on TCR internalization.
Similar results were obtained with ligand-induced
TCR endocytosis (data not shown).
Fig. 4. Phosphorylation in£uences the distribution of AP2 com-
plexes at the plasma membrane. Cells were incubated without
(a and b) or with (c and d) 120 nM of calyculin A for 1 h. The
cells were subsequently ¢xed, permeabilized, stained with anti-
K-adaptin mAb and analyzed by confocal laser scanning mi-
croscopy.
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3.5. Spontaneous endocytosis dependent on
tyrosine- or leucine-based motifs is also blocked
by PP2A inhibitors
Although PP2A inhibitors blocked both ligand-
and PKC-mediated TCR endocytosis we could not
exclude the possibility that this e¡ect was restricted
to TCR phosphorylation. Therefore, we next looked
at spontaneous endocytosis of receptors containing
phosphorylation-independent receptor-sorting mo-
tifs. As examples we used the transferrin receptor
and a chimeric CD4/3-SA molecule. Both receptors
are endocytosed via clathrin-coated pits and vesicles
[32,41]. The transferrin receptor is constitutively en-
docytosed dependent on a tyrosine-based (Tyr-Thr-
Arg-Phe) endocytosis motif and the CD4/3-SA chi-
mera is constitutively endocytosed dependent on a
di-leucine-based (Asp-Lys-Gln-Thr-Leu-Leu) recep-
tor-sorting motif [32]. Transferrin receptor endocyto-
sis was measured by uptake of transferrin^£uores-
cein. The cells were pre-incubated with calyculin A
(60 nM), okadaic acid (500 nM) or tautomycin
(1000 nM) followed by incubation with transferrin^
£uorescein for various periods. Transferrin uptake
was subsequently measured by FACS analysis. Caly-
culin A and okadaic acid strongly inhibited transfer-
rin uptake, whereas tautomycin did not show any
inhibitory e¡ect (Fig. 6A). Likewise, calyculin A se-
Fig. 5. Phosphorylation-induced T cell receptor endocytosis is blocked by PP2A inhibitors. Cells were incubated with calyculin A (A),
okadaic acid (B), or tautomycin (C) at the indicated concentrations for 1 h at 37‡C. The cells were subsequently incubated with PDB,
the TCR ligand mAb F101.01, or with medium in the continuous presence of phosphatase inhibitors for one additional hour at 37‡C.
The cells were stained for FACS analysis as described in Section 2. Mean £uorescence intensity (MFI) was recorded and used in the
calculation of percent anti-TCR/CD3 binding (MFI of cells treated with PDB/F101.01 and phosphatase inhibitor)/(MFI of cells only
treated with phosphatase inhibitor)U100%. (D) Cells were incubated with calyculin A (60 nM), okadaic acid (500 nM), tautomycin
(1000 nM), or left untreated for 1 h at 37‡C. The cells were subsequently incubated with various concentrations of PDB in the contin-
uous presence of phosphatase inhibitors for one additional hour at 37‡C. The cells were stained for FACS analysis as described
above.
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verely inhibited spontaneous CD4/3-SA endocytosis
(Fig. 6B). Finally, £uid-phase endocytosis as mea-
sured by internalization of £uorescein^dextran was
not reduced by the PP2A inhibitors (data not
shown).
Taken together, these results demonstrated that
PP2A inhibitors impaired clathrin-mediated endocy-
tosis in general at concentrations which coincided
with PP2A concentrations that inhibited L2-adaptin
de-phosphorylation.
4. Discussion
In this study, we found that L2-adaptin is consti-
tutively de-phosphorylated by PP2A and phosphory-
lated by a staurosporine-sensitive kinase in vivo.
Furthermore, we found a correlation between
L-adaptin phosphorylation and inhibition of clath-
rin-mediated endocytosis in general. Thus, treatment
of cells with PP2A inhibitors at concentrations that
inhibited L-adaptin de-phosphorylation abolished
clathrin-mediated endocytosis. In contrast, treatment
of cells with the PP1 inhibitor tautomycin did not
inhibit de-phosphorylation of L-adaptin and did
not a¡ect clathrin-mediated endocytosis. Our results
agree with previous studies which have indicated that
PP2A plays a role in de-phosphorylation of coat
proteins [30,31]. Thus, the mitotic inhibition of clath-
rin-coated vesicle invagination in vitro was reversed
by diluting cytosol and this reversal was sensitive to
okadaic acid [30]. Furthermore, de-phosphorylation
of amphiphysin 1 and 2 in vitro was partially inhib-
ited by okadaic acid [31]. We could not exclude that
L-adaptin in untreated cells was phosphorylated to
some extent. However, we could conclude that the
mobility shift induced by PP2A inhibitors was caused
by phosphorylation, as this shift was completely re-
versed by alkaline phosphatase treatment of the ly-
sate. The mobility shift of L-adaptin was observed as
shortly as 10 min after treatment of cells with PP2A
inhibitors. Thus, cycles of de-phosphorylation/phos-
phorylation of L-adaptin must take place in vivo.
Treatment of whole-cell lysate with PP2A inhibitor
did not induce L-adaptin phosphorylation, demon-
strating that the kinase responsible for L-adaptin
phosphorylation was not active in the lysis bu¡er.
This could be due to dilution of the cytosol as the
lysis bu¡er did not contain ATP required for kinase
activity.
In contrast to a previous study [25], we found that
phosphorylated AP2 complexes were found at the
plasma membrane using confocal laser scanning mi-
croscopy. This discrepancy might be explained by the
use of di¡erent techniques and cells in determining
AP2 distribution in these studies. Interestingly, we
found that phosphorylated AP2 complexes were
evenly distributed at the plasma membrane com-
pared to non-phosphorylated AP2 complexes, which
were predominantly found in aggregates. This could
be explained by an impaired binding of phosphory-
lated AP2 with clathrin as previously described [25].
Thus, it could be speculated that although phosphor-
Fig. 6. Transferrin receptor and CD4/3-SA endocytosis is
blocked by PP2A inhibitors. (A) Cells were incubated with caly-
culin A (60 nM), okadaic acid (500 nM), tautomycin (1000 nM),
or left untreated for 1 h at 37‡C followed by incubation with
transferrin^£uorescein for various periods. MFI were recorded
and used to calculate the percentage of endocytosed transfer-
rin^£uorescein. (B) Cells were incubated with calyculin A
(60 nM) or left untreated for 1 h at 37‡C. The cells were pre-
pared for FACS analysis as described in Section 2.
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ylated AP2 complexes are recruited to the plasma
membrane, they cannot bind to clathrin and conse-
quently no aggregation of phosphorylated AP2 com-
plexes is seen.
In addition to clathrin, phosphorylation of other
components of the endocytosis apparatus like amphi-
physin, Eps15, and epsin inhibits their binding to AP
complexes [30,31,42]. From these studies, it should
be expected that phosphorylation-induced inhibition
of coat assembly would inhibit clathrin-mediated en-
docytosis in general. We extended these studies and
found a close correlation between L-adaptin phos-
phorylation and impairment of clathrin-mediated en-
docytosis for three di¡erent receptors. Our results
indicated that a common mechanism in clathrin-
mediated endocytosis is impaired following treatment
with PP2A inhibitors, as these receptors use di¡erent
endocytosis motifs but are all endocytosed via clath-
rin-coated pits and vesicles. In agreement with pre-
vious studies [25,31,42], this could be induced by
phosphorylation of L-adaptin and/or other proteins
involved in clathrin-mediated endocytosis as the con-
centrations of PP2A inhibitors required to inhibit de-
phosphorylation of L-adaptin were identical to the
concentrations required to inhibit endocytosis.
We found that a staurosporine-sensitive kinase is
responsible for the constitutive phosphorylation of L-
adaptin. Experiments using the PKA inhibitor
KT5720 suggested that PKA, which has been impli-
cated to take part in the endocytosis process, might
be responsible for part of the phosphorylation
[43,44]. PKA consensus phosphorylation sites are
found in L-adaptin but they all reside outside the
hinge domain, which is thought to bind clathrin.
However, analyses using PKA speci¢c activators
and inhibitors seemed to exclude the possibility
that PKA is involved in L-adaptin phosphorylation
in vivo. Interestingly, KT5720 is a derivative of the
broad-spectrum kinase inhibitor K252a that has been
shown to inhibit phosphorylation of amphiphysin
[31] and it is thus likely that the partial inhibition
of L-adaptin phosphorylation by KT5720 is caused
by cross-inhibition of other kinases than PKA. A
kinase likely to participate in L-adaptin phosphory-
lation would be casein kinase II that has the ability
to phosphorylate the clathrin b light chain in vitro
[24,45]. However, we found that the casein kinase II
inhibitor DRB did not inhibit L-adaptin phosphory-
lation indicating that casein kinase II is not involved
in phosphorylation of L-adaptin in vivo. Thus, the
exact kinase(s) involved in L-adaptin phosphoryla-
tion remains to be identi¢ed. The L-adaptin mobility
shift assay presented in this study is a potent assay to
study the e¡ect of various kinase inhibitors and acti-
vators on L-adaptin phosphorylation and we are
presently using this assay to further characterize the
L-adaptin kinase.
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